1-4 of 4
A. Ackerstein
Close
Sort by
Journal Articles

Immunotherapy With Recombinant Human Interleukin-2 and Recombinant Interferon-α in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation

A. Nagler, A. Ackerstein, R. Or, E. Naparstek, S. Slavin
Journal: Blood
Blood (1997) 89 (11): 3951–3959.
https://doi.org/10.1182/blood.V89.11.3951
Published: 1997
Journal Articles

Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT [letter; comment]

S Slavin, E Naparstek, A Nagler, Y Kapelushnik, A Ackerstein, R Or
Journal: Blood
Blood (1996) 87 (9): 4011–4013.
https://doi.org/10.1182/blood.V87.9.4011.bloodjournal8794011
Published: 1996
Journal Articles

Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation

S Slavin, E Naparstek, A Nagler, A Ackerstein, S Samuel, J Kapelushnik, C Brautbar, R Or
Journal: Blood
Blood (1996) 87 (6): 2195–2204.
https://doi.org/10.1182/blood.V87.6.2195.bloodjournal8762195
Published: 1996
Journal Articles

Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders

A Ackerstein, E Kedar, S Slavin
Journal: Blood
Blood (1991) 78 (5): 1212–1215.
https://doi.org/10.1182/blood.V78.5.1212.1212
Published: 1991